A detailed history of Black Rock Inc. transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 883,081 shares of IGMS stock, worth $6.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
883,081
Previous 757,963 16.51%
Holding current value
$6.09 Million
Previous $7.31 Million 17.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.51 - $11.47 $814,518 - $1.44 Million
125,118 Added 16.51%
883,081 $6.07 Million
Q1 2024

May 10, 2024

SELL
$8.68 - $17.36 $39,120 - $78,241
-4,507 Reduced 0.59%
757,963 $7.31 Million
Q4 2023

Feb 13, 2024

SELL
$3.94 - $8.79 $427,277 - $953,240
-108,446 Reduced 12.45%
762,470 $6.34 Million
Q3 2023

Nov 13, 2023

BUY
$6.66 - $10.64 $91,541 - $146,246
13,745 Added 1.6%
870,916 $7.27 Million
Q2 2023

Aug 11, 2023

BUY
$8.86 - $14.0 $767,054 - $1.21 Million
86,575 Added 11.23%
857,171 $7.91 Million
Q1 2023

May 12, 2023

SELL
$13.74 - $25.76 $256,099 - $480,140
-18,639 Reduced 2.36%
770,596 $10.6 Million
Q4 2022

Feb 13, 2023

BUY
$15.45 - $26.02 $761,731 - $1.28 Million
49,303 Added 6.66%
789,235 $13.4 Million
Q3 2022

Nov 14, 2022

BUY
$15.42 - $27.01 $250,143 - $438,156
16,222 Added 2.24%
739,932 $16.8 Million
Q2 2022

Aug 12, 2022

BUY
$13.27 - $25.5 $383,317 - $736,593
28,886 Added 4.16%
723,710 $13 Million
Q1 2022

May 12, 2022

BUY
$13.42 - $29.73 $239,775 - $531,185
17,867 Added 2.64%
694,824 $18.6 Million
Q4 2021

Feb 10, 2022

BUY
$27.59 - $66.39 $999,309 - $2.4 Million
36,220 Added 5.65%
676,957 $19.9 Million
Q3 2021

Nov 09, 2021

BUY
$65.76 - $90.65 $521,871 - $719,398
7,936 Added 1.25%
640,737 $42.1 Million
Q2 2021

Aug 11, 2021

BUY
$57.98 - $96.6 $36.7 Million - $61.1 Million
632,801 New
632,801 $52.7 Million

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $200M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.